ArticleScientific reports2025
SHLP2 restores pre-osteoblastic cells against oxidative stress-induced inflammaging.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Small but mighty: mitochondrial DNA at the centre of retrograde signalling.Cell communication and signaling : CCS · 2026Review
- Altered placental expression of small humanin-like peptides in gestational diabetes mellitus.Upsala journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to evaluate the cytoprotective effects of the mitochondrial-derived peptide, Small Humanin-Like Peptide-2 (SHLP2), on pre-osteoblastic cells exposed to sub-toxic oxidative stress, with the aim of preserving bone homeostasis under conditions of inflammaging. Pre-osteoblastic MC3T3-E1 cells were cultured under sub-toxic oxidative stress induced by 600 µM H2O2. The study evaluated the effects of SHLP2 (at 10 µM concentration) through assays for mitochondrial activity, reactive oxygen species (ROS) generation, apoptosis markers, and osteogenic differentiation. Quantitative polymerase chain reaction, alkaline phosphatase (ALP) staining, and Alizarin Red S biomineralization assays were performed to assess gene expression, osteogenic activity, and biomineralization. Oxidatively stressed but untreated cells served as the positive control (PC), while oxidative stress-free cells were used as the mock control. Statistical analyses were performed using one-way ANOVA and t-tests. SHLP2 treatment significantly (p < 0.001) improved cell viability and reduced ROS activity in oxidatively stressed cells. A significant (p < 0.001) decrease in apoptotic markers, including p53 and BAX, and an increase in anti-apoptotic BCL-2 levels, were observed. Additionally, SHLP2 treatment upregulated key osteogenic markers, including RUNX2, OSX, and ALP, compared to PC. When compared to the mock group, SHLP2 restored ALP activity to 95.6% by day 14. By day 21, the biomineralization assay demonstrated 94.92% activity following SHLP2 treatment. SHLP2 treatment effectively mitigates oxidative stress in pre-osteoblastic cells, providing apoptosis protection and preserving osteogenic activity. These findings underscore the potential of SHLP2 as an adjuvant therapeutic agent for enhancing the tissue microenvironment in conditions such as periodontitis and inflammaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.